**021 POLYMORPHISMS IN APOPTOTIC AND IMMUNOREGULATORY RELATED GENES ARE ASSOCIATED WITH AN INCREASED RISK OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)**

A. Enjuanes1, Y. Benavente1, F. Bosch1, D. Colomer1, S. Pérez-Álvarez1, I. Martin-Guerrero1, O. Reina2, M. Ardanaz4, P. Jares1, A. García-Onrubia1, M.A. Puñana1, E. Montserrat1, S. De Sanjosé1, E. Campo1
1Pathology Department, Hospital Clinic-IDIBAPS, Barcelona, Spain, 2Cancer Unit, Catalan Institute Of Oncology, Barcelona, Spain, 3Hematology Department, Hospital Clinic, Barcelona, Spain, 4Genetics Department, Facultad Medicina Y Odontologia, Vizcaya, Spain

Family and epidemiologic studies have suggested an inherited susceptibility for CLL. To identify low penetration susceptibility alleles for CLL risk, we genotyped 768 SNPs in 689 cases of CLL and 723 controls from Northeast Spain. We have performed an approach selecting non-synonymous SNPs in 618 genes involved in cancer biology, and a second approach focused on potentially functional and marker SNPs in 30 candidates. Genotyping was carried out using Illumina Platform. To test the hypothesis of association between SNPs and CLL risk, multivariate methods based on logistic regression analyses were used. To quantify the degree of the association, odds ratios (OR) and 95% confidence intervals (95% CI) were calculated for each group under the four alternative models. All analyses were adjusted for age, gender and center of recruitment. We assessed the robustness of the findings by calculating EDR. We found a strong association with CLL risk after stringent adjustment for multiple testing for six variants: CCNH rs2266690 (OR, 0.63; 95% CI, 0.53-0.74), APAF1 rs1702868X OR, 0.42; 95% CI, 0.29-0.61), IL6 rs4505265, CASP8 rs1854585 (OR, 0.56; 95% CI, 0.44-0.72), NOS2A rs2277925 (OR, 0.70; 95% CI, 0.57-0.84) and CCRC7 rs316687 (OR, 0.49; 95% CI, 0.24-0.87). Moreover, we found association with CLL risk for 22 haplotypes in 17 candidate genes related to apoptosis and immunomodulation. Finally, we evaluated in silico the potential influence of these SNPs on the mRNA expression. Minor allele for APAF1 rs1702868X and IL6 rs4505265 in the germ-line may be associated with lower mRNA levels, no expression differences were observed for CCRC7 rs316687, whereas NOS2A could not be assessed. Common genetic variants in apoptosis and immunomodulation related genes are associated with an increased CLL risk.

**022 DOUBLING TIME OF SOLUBLE CD23 (SCD23D): A POWERFUL INDEPENDENT PROGNOSTIC FACTOR FOR STAGE A UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL)**

N. Meuleman1, B. Stamatopoulos1, M. Azerad2, C. Springinger1, H. El Housni1, L. Lagneaux1, D. Bron1
1Department of Experimental and Clinical Hematology, Institut Jules Bordet, Brussels, Belgium

**Background:** We have previously reported that sCD23 level is correlated with stages, prognosis and overall survival (OS) of patients (pts) with CLL. We evaluated prospectively the sCD23D as a prognostic factor for time to treatment (TTT) and OS in untreated Binet stage A CLL pts and we compared it to the most commonly used biological prognostic factors, factors: ZAP-70 and CD38 expression.

**Methods:** sCD23 level was prospectively evaluated by a commercially available enzyme-linked immunosorbent assay (ELISA). ZAP-70 and CD38 expression were determined in leukemic cells by flow cytometry, and positive expression was respectively defined as >20% and >7% positive cells. LPL expression was measured by real time PCR on cDNA from CD19 purified cells and optimal cut-off was determined by ROC curve analysis.

**Results:** Untreated stage A CLL pts were monitored for more than 15 years. 56 are evaluable for correlation between sCD23D and new prognostic factors. Median age is 63 (43-89) years. The median follow-up is 64 (6-176) months. The sCD23D is clearly correlated with a progression of the disease: median TTT and OS were respectively 20 and 83 months in pts with sCD23D < 9 months comparing to 121 and 177 months in pts with sCD23D > 9 months (p < 0.001). Mutational status, ZAP-70 and LPL expression were also strong predictors for TTT (p = 0.0001) and OS (respectively p = 0.0045; p = 0.0001 and p = 0.0025) but CD38 and LDT had only a significant impact on TTT (respectively p = 0.0338 and p = 0.0001). More interestingly, among poor prognostic pts (Unmutated, ZAP-70+, LPL+ and CD38+), sCD23D allows to isolate 2 different populations: one with a very aggressive evolution (TTT < 15 months) and another with a more indolent evolution (TTT > 5 years). In a Cox multivariate regression analysis, sCD23D is the sole independent prognostic marker for TTT (p = 0.0027).

**Conclusion:** sCD23D is a powerful prognostic factor for TTT and OS in pts with untreated stage A CLL and refine the high risk population defined by widely accepted prognostic factors. These observations support the introduction of sCD23 evaluation into the routine assessment of CLL pts.

**023 QUANTITATIVE GENE EXPRESSION ANALYSIS OF SURROGATE MARKERS FOR GENETIC RISK GROUPS AND SURVIVAL IN CLL**

D. Kienle1, A. Benner2, C. Laeufle1, D. Winkler1, A. Bühler1, T. Zenz1, A. Habermann1, R. Dalla-Favera3, P. Lichter4, H. Döhner1, S. Stilgenbauer1
1Internal Medicine II, University of Ulm, Ulm, Select your country, 2Central Unit Biostatistics, German Cancer Research Center, Heidelberg, Germany, 3Genetics and Development, Columbia University, New York, Germany, 4Molecular Genetics, German Cancer Research Center, Heidelberg, Germany

**Introduction/Background:** In CLL, numerous surrogate markers for genetic features such as VH mutation status have been described. Their detailed relation to the most important genetic subgroups, i.e. VH mutation status, V3-21 usage, del11q22-23 (11q-), del(17p13) (17p-), and their value as prognostic markers in the context with established prognostic factors is largely unknown.

**Materials and Methods:** Transcript levels of 18 candidate genes (ADAM29, ATM, CLL1, DMD, GL01, HSC1, KIAA0977, LPL, MGO9913, PCD9H, PEG10, SEPT10, TG7, TCL1, TP53, VIM, ZAP70, ZNF2) were determined by real-time quantitative RT-PCR (qRT-PCR) and investigated regarding their predictive value for genetic subgroups and survival in 151 CD19 purified patients samples.

**Results:** Best assignment of VH mutation status was achieved by LPL and ZAP70, followed by ZC3H7B, which was overexpressed VH mutated CLL. Patients at genetic risk (VH unm. or V3-21 usage or 11q-13 or 17p-) were best assigned by ZAP70, in which a determination by qRT-PCR yielded better results compared to the FACS method. When applying a hierarchical risk model (risk 17p- > 11q- > VH unm. or V3-21 usage > VH mutated patients) high classification rates occurred with any individual marker, which could be improved using a marker combination of 5 genes. Still, a reliable discrimination of 11q- or 17p- from VH unmutated patients without these abnormalities was not achieved. In multivariate survival analysis, LPL was the strongest survival predictor among the candidate genes; however, when including genetic factors, the surrogate markers lost their independent prognostic significance.

**Conclusions:** Screening for patients at genetic risk can be performed using ZAP70 or LPL, a marker combination reduces misclassifications. A distinction of 11q- or 17p- from other risk patients is not possible. The prognostic impact of the surrogate markers is inferior compared to the established genetic factors.

**024 B CELL RECEPTOR-DEPENDENT INDUCTION OF CCL3 AND CCL4 BY CHRONIC LYMPHOCYTIC LEUKEMIA B CELLS IS ASSOCIATED WITH ZAP-70 AND INDEPENDENT OF SYC INHIBITION**

J.A. Burger1, M. Niedermeier1, A. Bürkle1, E. Hartmann1, W.G. Wierda1, M.J. Keating1, A. Rosenwald2
1Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, Houston, United States, 2Department of Medicine, Division of Hematology/Oncology, Fredrick University Hospital, Freiburg, Germany, 3Institute of Pathology, University of Würzburg, Würzburg, Germany

Nurse-like cells (NLC) provide survival- and drug resistance-signals to CLL cells in vitro, and NLC can be detected in situ in lymphoid tissues from CLL patients. High level expression of CCL8 makes NLC comparable to CD86+lymphoma-associated macrophages in follicular lymphoma, which are associated with an aggressive clinical course and poor outcome. To dissect the molecular cross talk between CLL and NLC, we examined gene expression profiles of CLL cells before and after co-culture with NLC. NLC induced a homogeneous gene expression response with high-level expression of B cell maturation antigen (BCMA, TNFRSF17) and CD27, chemokine ligands, CCL3 and CCL4. Levels of CCL3 expression and CCL4 expression correlated with the ZAP-70 expression. Supernatants from CLL cells co-cultured with NLC revealed high CCL3 and CCL4 protein levels (up to >10 ng/ml). BCR triggering also induced a rapid (starting after 2h) and robust CCL3 and CCL4 secretion by CLL cells with a maximum response at 10 μg/mL anti-IgM or higher. In contrast anti-CD40 mAbs had no effect, and CCL3 and CCL4 induction was not affected by the spleen tyrosine kinase (Syk) inhibitor piceatannol. The correlation to ZAP-70 expression and lack of inhibition using piceatannol suggest that BCR-induced secretion of these chemokines depends upon ZAP-70 rather than Syk. Conditioned supernatants from CLL cells containing <10 ng/mL of CCL3 and CCL4 stimulated chemotaxis and actin polymerization in normal lymphocytes, indicating bioactivity of the secreted chemokines. CLL patients displayed higher CCL3 and CCL4 plasma levels than healthy donors, suggesting that these chemokines are secreted in relevant
Correlation of the expression with ZAP-70, and lack of inhibition using piceatannol provide further evidence for the importance of ZAP-70 in BCR signaling in CLL cells.

025 ABNORMAL SERUM FREE LIGHT CHAIN RATIOS ARE ASSOCIATED WITH POOR SURVIVAL IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA

G. Mead1, S. Harding1, R. Holder2, C. Fegan3, C. Pepper3, D. Oscier4, G. Pratt5

1IDRL, The Binding Site Ltd, Birmingham, United Kingdom, 2General Medicine, University of Birmingham, Birmingham, United Kingdom, 3Department of Haematology, Royal Rouencout Hospital, Rouen, United Kingdom, 4Department of Haematology, Royal Rouencout Hospital, Rouen, United Kingdom, 5CRUK Institute for Cancer Studies, University of Birmingham, Birmingham, United Kingdom

Serum free light chains (FLC) have prognostic significance in monoclonal gammopathy of uncertain significance, solitary plasmacytoma of bone, multiple myeloma, Waldenstrom's macroglobulinaemia and AL amyloidosis. The incidence of abnormal FLC in other lymphoid malignancies including chronic lymphocytic leukaemia (CLL) is unclear with only one published report which found 8/18 CLL patients with an abnormal FLC. There have been no studies correlating FLC with other biological variables and clinical outcomes in CLL or lymphoma. This was a retrospective study that analysed random serum FLC levels taken at varied time points in 226 CLL patients (183 Stage A, 18 Stage B, 16 Stage C, 9 unknown, mean age 74, male: female ratio 2.2) treated at 3 separate hospitals in the UK and correlated serum FLC with biological and clinical markers. Using Kaplan-Meier survival hazards, abnormal FLC ratio is a significant indicator of poor survival (n=226, Log rank Mantel-Cox p=0.001) and also to first treatment. Using Cox regression analysis (n=142 with complete data sets), Zap70, B2M and age in a forward stepwise analysis and showed 4 independent prognostic variables Zap70 (p=0.001), B2M (p=0.002), mutation status (p=0.003) and FLC ratio (p=0.008). An abnormal free light chain ratio contributes significantly and independently to the prediction of a worse outcome. Serum FLC at diagnosis needs to be studied prospectively in CLL patients and the biological rationale for its adverse impact needs investigating.

026 CLINICAL CASPASE ACTIVATION IN CLL BY GCS-100, A NOVEL CARBOHYDRATE, IN A PHASE 2 STUDY

F.E. Cotter1, J. Gribben2, M. Strevel3, R. Auer4, D. Smith5, C. Akerman6, T. Boyd7, J. Gribben8, G.T. Tidmarsh9

1Centre for Haematology, Barts and the London School of Medicine, London, United Kingdom, 2Centre for Haematology, Barts and the London School of Medicine, London, United Kingdom, 3Centre for Haematology, Barts and the London School of Medicine, London, United Kingdom, 4Oncology, Northwest Cancer Specialists, Vancouver, WA, United States, 5Oncology, Center for Cancer of Florida, Ocoee, FL, United States, 6Oncology, Central Indiana Cancer Centers, Indianapolis, IN, United States, 7Oncology, Yakima Valley Memorial Hospital/North Star Lodge, Yakima, WA, United States, 8VP, Prospect Therapeutics, Woburn, MA, United States

Chronic lymphocytic leukaemia (CLL) is characterised by deregulation of multiple cellular pathways. GCS-100, a modified citrus pectin, with the ability to bind the carbohydrate binding domain of Galectin 3. It has previously been demonstrated to have anti-CLL effects in vitro, even in the context of fludarabine resistance (Lugano 2005). We have elucidated further the mechanisms of action of GCS-100 demonstrating inhibition of proliferation, induction of apoptosis and accumulation of cells in sub-G1 and G1 phases with reduction of cells in S and G2/M phase. Both the caspase-8 and -9 pathways were activated. Significantly a dose and time dependent decrease in Mcl-1 and Bcl-xL levels occurred. This was accompanied by a rapid induction of Noxa protein. Bcl-2, Bax, Bak, Bim, Bad, Bid and galectin 3 remained unchanged. Following GCS-100 treatment cell cycle proteins were examined and upregulation of the cell cycle inhibitor p21 was seen with concurrent reduction of the pro-cycling proteins cyclin E2, cyclin D1, cyclin D2 and CDK6 occurred. Furthermore, there is a reduction in signal transduction in the form of reduced activated IkBα, IκB and акт. In a clinical Phase 2 study (NCT00514696), patients with relapsed CLL were treated with GCS-100 by IV infusion and concurrent studies of protein expression of the CLL cells by Western blotting were performed. Activation of Caspase 8 and 9 were seen maximal 6 hours after infusion of GCS-100 and may correlate with clinical response. This study provides evidence for clinical and biological activity for GCS-100 in CLL in relapsed disease.